SecBot SecBot
PRESS-RELEASE ·Filed Jun 3, 2026

CNXU

Conexeu Sciences Inc.
NEUTRAL
Impact 2/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

This is a ceremonial event with no material financial or operational impact. Monitor for future regulatory milestones (510(k) submission in early 2027) and capital raises typical for preclinical-stage biotechs.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
CNXU ▼ -58.22% at T+60d
NEUTRAL call -58.22% · α vs SPY -60.72% · entry $16.85 → $7.04
Entry = T+0 close
Jun 3, 2026
via day close
T+1d
-5.04%
call -5.04% · α -5.44%
$16.00
settled 5mo ago
T+5d
-22.73%
call -22.73% · α -18.91%
$13.02
settled 5mo ago
T+20d
-35.55%
call -35.55% · α -34.55%
$10.86
settled 4mo ago
T+60d
-58.22%
call -58.22% · α -60.72%
$7.04
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Conexeu Sciences Inc. (CNXU) announced it will ring the Nasdaq Closing Bell on June 10, 2026, to celebrate its recent public listing. The press release highlights the company's preclinical-stage regenerative tissue platform (CXU™) and lead device candidate Ten Minute Tissue™, with a planned 510(k) submission in early 2027. This is a ceremonial milestone with no financial data or material business update.

Key Facts

  • Conexeu will ring the Nasdaq Closing Bell on June 10, 2026, in celebration of its recent public listing.
  • The company is a preclinical-stage regenerative tissue platform company with no approved products.
  • Lead device candidate Ten Minute Tissue™ is investigational; safety and effectiveness not established.
  • Anticipated 510(k) submission in early 2027 for initial indication, subject to regulatory review.
  • No financial results, guidance, or material business developments were disclosed in the press release.

Financial Impact

No financial data provided in the press release.

Risk Factors

  • Preclinical-stage company with no approved products or revenue.
  • 510(k) submission timeline is subject to regulatory review and may be delayed.
  • Forward-looking statements involve inherent uncertainties; actual results may differ materially.

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3306034
8 reports for CNXU
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CNXU — sortable, filterable
TypeNow
Oct 27, 2026
today
8-K
BEARISH ★ 5/10
$2.96awaiting T+1—$2.95 (+0.34%)
Oct 20, 2026
7d ago
8-K
BEARISH ★ 6/10
$3.33 $3.30▲ +0.90%▼ −0.28%$2.95 (+11.41%)
Oct 15, 2026
12d ago
Press Release
MIXED ★ 5/10
$3.06 $3.29▲ +7.52%▲ +7.09%$2.95 (−3.59%)
Oct 6, 2026
21d ago
Press Release
NEUTRAL ★ 3/10
$3.66 $3.64▼ −0.55%▼ −0.31%$2.95 (−19.40%)
Jun 29, 2026
17w ago
3
NEUTRAL ★ 2/10
$10.24 $10.92▲ +6.64%▲ +5.86%$2.95 (−71.19%)
Jun 23, 2026
17w ago
Insider Buy
NEUTRAL ★ 2/10
$10.69 $10.22▼ −4.40%▼ −4.54%$2.95 (−72.40%)
Jun 3, 2026
20w ago
Press Release
NEUTRAL ★ 2/10
$16.85 $16.00▼ −5.04%▼ −5.44%$2.95 (−82.49%)
May 14, 2026
23w ago
Insider Cluster
NEUTRAL ★ 4/10
—awaiting T+1——
Showing 8 of 8

US Market Status

Market Closed — Opens Wed (15h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026